In house ELISA based on recombinant ORF2 protein underline high prevalence of IgG anti-hepatitis E virus amongst blood donors in south Brazil

PLoS One. 2017 May 9;12(5):e0176409. doi: 10.1371/journal.pone.0176409. eCollection 2017.

Abstract

Hepatitis E Virus (HEV) is a zoonotic pathogen responsible for causing acute hepatitis in human, especially in developing countries. Diagnosis of HEV usually relies on the detection of antibodies mostly by enzyme-linked immunosorbent assay (ELISA). In the present study, we designed a new indirect ELISA (iELISA) based on a short recombinant peptide derived from the capsid protein (ORF2p) and demonstrated its potential for detecting human IgG against HEV genotype 3. The best polystyrene plate (Maxisorp®), optimal ORF2p coating antigen concentration (0,67μg/well) and primary antibody dilution (1:100) were determined. This iELISA showed a sensitivity of 91.4% and specificity of 95.9%. The comparison of our in house iELISA with a commercial assay (RecomWell, Mikrogen®) showed 94.25% of agreement and a kappa index of 0.88. The ORF2 recombinant ELISA was used to screen 780 blood donors for anti-HEV IgG and we found that 314 (40,25%) of these donors were IgG positive. This high prevalence of antibodies suggests, for the first time, that the Southern Brazil region might be endemic to Hepatitis E Virus genotype 3.

MeSH terms

  • Blood Donors*
  • Brazil / epidemiology
  • Endonucleases / metabolism*
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Hepatitis E virus / immunology
  • Hepatitis E virus / isolation & purification*
  • Humans
  • Immunoglobulin G / immunology*
  • RNA-Directed DNA Polymerase / metabolism*
  • Recombinant Proteins / metabolism
  • Seroepidemiologic Studies

Substances

  • Immunoglobulin G
  • ORF2 protein, human
  • Recombinant Proteins
  • RNA-Directed DNA Polymerase
  • Endonucleases

Grants and funding

The author RF received financial support from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grant n° 485807/2013).